• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

    2/2/22 10:18:58 AM ET
    $CLGN
    Industrial Specialties
    Health Care
    Get the next $CLGN alert in real time by email
    SC 13G/A 1 zk2227166.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)*

    CollPlant Biotechnologies Ltd
    (Name of Issuer)

    Ordinary Shares, par value NIS 0.03 per share
     (Title of Class of Securities)

    19516Q208
    (CUSIP Number)

    December 31, 2021
     (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    CUSIP No. 19516Q208
    13G
     

    1
    NAME OF REPORTING PERSONS
     
    MEITAV DASH INVESTMENTS LTD.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
    547,730 (*)
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    547,730 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    547,730 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    5.52% (*) (**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 9,914,740 Ordinary Shares outstanding as of December 31, 2021 ( as reported on Bloomberg LP).

    2

     

    CUSIP No. 19516Q208
    13G
     

    1
    NAME OF REPORTING PERSONS
     
    Meitav Dash Provident Funds and Pension Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
    547,730 (*)
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    547,730 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    547,730 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    5.52% (*) (**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 9,914,740 Ordinary Shares outstanding as of December 31, 2021 ( as reported on Bloomberg LP).
     
    3

     
    Item 1.        (a)          Name of Issuer:

    CollPlant Biotechnologies Ltd.

                         (b)
    Address of Issuer's Principal Executive Offices:

    3 Sapir Street,
    Weizmann Science Park, Ness Ziona 74140,
    Israel

    Item 2.        (a)
    Name of Person Filing:

    1.
    MEITAV DASH INVESTMENTS LTD.
    2.
    Meitav Dash Provident Funds and Pension Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of the Meitav Dash Investments Ltd. (the "Subsidiaries").   Some of the securities reported herein are held by third-party client accounts managed by a subsidiary of the Reporting Person as portfolio managers, which subsidiary operates under independent management and makes independent investment decisions and has no voting power in the securities held in such client accounts.  The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or members of pension or provident funds, unit holders of mutual funds, and portfolio management clients.  Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.

    (b)
    Address of Principal Business Office:

    MEITAV DASH INVESTMENTS LTD. -– 30 Derekh Sheshet Ha-Yamim, Bene-Beraq, Israel

    Meitav Dash Provident Funds and Pension Ltd. – 30 Derekh Sheshet Ha-Yamim, Bene-Beraq, Israel
     
    (c)
    Citizenship:

    MEITAV DASH INVESTMENTS LTD. – Israel

    Meitav Dash Provident Funds and Pension Ltd. – Israel

    (d)
    Title of Class of Securities:

    Ordinary Shares, par value NIS 0.03 per share

    (e)
    CUSIP Number:

    19516Q208

    Item 3.
    Not applicable.

    4

    Item 4.
    Ownership:

      (a)
    Amount beneficially owned:

    See row 9 of cover page of the  reporting person.

    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Person or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, the Filing Person and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Person or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement, and each of Filing Person and Subsidiaries disclaims beneficial ownership of any such Ordinary Shares.

    As of December 31, 2021, the securities reported herein were held as follows:

       


    Ordinary Shares
       
    Percentage of total Ordinary Shares outstanding
     
    Meitav Dash Provident Funds and Pension Ltd.
       
    547,730
         
    5.52
    %
     
    (b)
    Percent of class:

    See row 11 of cover page of the reporting person

    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of the reporting person

    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of the  reporting person and note in Item 4(a) above

    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of the reporting person

    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of the reporting person and note in Item 4(a) above

    5

    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.
     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    6


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 02, 2022
     
    Meitav Dash Provident Funds and Pension Ltd.
     
    /s/ Hagai Oren
    By: Hagai Oren
    Title: CEO
     
    MEITAV DASH INVESTMENTS LTD.
     
    /s/ Ilan Raviv
    By: Ilan Raviv
    Title: CEO
     

    7

    EXHIBIT NO.       DESCRIPTION

    Exhibit 1
    Agreement of Joint Filing by and among the Reporting Persons, dated as of December 31, 2021.
     
    8
     
     
    Get the next $CLGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLGN

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    More analyst ratings

    $CLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      2/13/24 4:01:04 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      1/25/24 3:27:05 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      7/24/23 6:27:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

      CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel, April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing i

      4/15/25 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

      REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v

      8/19/21 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    SEC Filings

    See more
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      4/15/25 8:14:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 20-F filed by CollPlant Biotechnologies Ltd

      20-F - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      3/26/25 10:13:19 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      3/26/25 9:52:36 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Financials

    Live finance-specific insights

    See more
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

      -Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration

      11/27/24 7:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology

    $CLGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on CollPlant with a new price target

      Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75

      2/17/23 8:30:35 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

      HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously

      2/9/21 6:08:53 AM ET
      $CLGN
      Industrial Specialties
      Health Care